May 2, 2023 CEBINA GmbH
[PRESSWIRE] Vienna, Austria – 02.05.2003– CEBINA GmbH, Central European Biotech Incubator and Accelerator, today reveals the publication of the favorable outcomes of a Phase 2 medical research study that evaluated azelastine nasal spray as a brand-new method for minimizing viral load in the nose of SARS-CoV-2 favorable clients in the peer-reviewed journal Scientific Reports (1 ). Vaccines have actually been a beneficial tool to manage the COVID-19 pandemic, however have constraints that other complementary methods such as topical antivirals can resolve. Azelastine, an extensively utilized anti-histamine, was formerly recognized as an antiviral drug by CEBINA based upon in vitro activity versus SARS-CoV-2 and other infections, such as breathing syncytial (RSV) and influenza infections. The just recently released peer-reviewed post explains the results of the Phase 2 medical research study CARVIN carried out in Germany that checked azelastine nasal spray in SARS-CoV-2 contaminated people. The research study, collectively moneyed by CEBINA and URSAPHARM Arzneimittel, was an evidence of idea effectiveness trial, randomized, double-blinded, and placebo-controlled, including 90 SARS-CoV-2 favorable volunteers who got either placebo or azelastine nasal spray for a duration of 11 days. Treatment with azelastine nasal sprays led to a higher reduction in mean viral load compared to that determined in the placebo group at all the timepoints after initiation of treatment, without unfavorable health occasions. “The publication of these information on azelastine effectiveness versus the SARS-CoV-2 infection shows that azelastine nasal spray is an appealing service to fight viral infections in the
Learn more